Investor Relations
Vitro Diagnostics dba Vitro Biopharma develops and commercialize adult stem cell technology for applications in stem cell research, drug development and therapeutic products for treatment a vast variety of diseases and conditions. We offer a series of tools to promote the development of stem cell research and clinical applications focusing on Mesenchymal Stem Cells (MSCs).
Become an Investor: Call (303) 999-2137
Vitro Diagnostics, Inc. (OTCPK:VODG)
Company Information
Vitro Biopharma
4621 Technology Drive
Golden, CO 80403
303-999-2130
www.vitrobiopharma.com
Investor Relations
John Evans
CFO & Director
john@vitrobiopharma.com
303-999-2137
wwww.vitrobiopharma.com
Transfer Agent
Securities Transfer Corporation
2591 Dallas Parkway, Suite 102
Frisco, TX 75034
469-633-0101
www.stctransfer.com
Share Statistics
Outstanding: 46,194,200
(As of June 26th, 2018)
Investor News
Vitro Biopharma 2nd Quarter ended April 30th 2020 Financial Results of Operations
Golden, Colorado-June 25th, 2020-Vitro Diagnostics, Inc. (OTCQB: VODG), dba Vitro Biopharma, announced its 2nd quarter ended April 30th, 2020 financial results of operations. Vitro Diagnostics Inc. (“Vitro Biopharma”) announced a reduction in 2nd quarter revenues...
Vitro Biopharma Signs MOU with GIOSTAR for COVID-19 IND Using AlloRx Stem Cells
Golden, Colorado—June 2, 2020—Vitro Diagnostics, Inc. (OTCPK: VODG), dba Vitro entered into an exclusive Memorandum of Understanding (MOU) with Global Institute of Stem Cell Therapy and Research, Inc. (“GIOSTAR”) a leading stem cell research institute based in San...
Vitro Biopharma Submits IND Application to FDA for AlloRx Stem Cell(R) Therapy of COVID-19
GOLDEN, CO / ACCESSWIRE / April 21, 2020 / Vitro Diagnostics, Inc. (OTCPINK:VODG), dba Vitro Biopharma announced the filing an investigational new drug (IND) application with the FDA for clinical use of AlloRx Stem Cells® in the treatment of COVID-19 patients in the...
Vitro Biopharma First Quarter 2020 Financial Results of Operations
Golden, Colorado-March 26, 2020- Vitro Diagnostics, Inc. (OTCPK: VODG), dba Vitro Biopharma, announced its 1st quarter ended January 31st, 2020 financial results of operations. Vitro Diagnostics Inc. (“Vitro Biopharma”) is pleased to announce a record 1st comparative...
Vitro Biopharma 2019 CEO Shareholder Letter: Record Revenues Leading to Further Growth into 2020
Golden, Colorado—January 23, 2020—Vitro Diagnostics, Inc. (OTCQB: VODG), dba Vitro Biopharma, announced its CEO letter to its shareholders including discussion of its 2019 results of operations ended October 31st 2019 and its expansion plans for 2020. Dear...
Vitro Biopharma Announces up to a $1,000,000 Private Offering of Series A Convertible Preferred and Warrants
Golden, Colorado – January 22, 2020-Vitro Diagnostics, Inc. (OTCQB: VODG), dba Vitro Biopharma announced a private placement of Units consisting of Series A Convertible Preferred Stock (“Series A Preferred”), Class A Warrants and Class B Warrants. . The Company has...
Vitro Biopharma 3rd Quarter ended July 31st 2019 Financial Results of Operations
Vitro Biopharma 3rd Quarter ended July 31st 2019 Financial Results of Operations Golden, Colorado-September 25th, 2019-Vitro Diagnostics, Inc. (OTCQB: VODG), dba Vitro Biopharma, announced its 3rd quarter ended September 24th 2019 financial results of operations....
Vitro Biopharma 2nd Quarter ended April 30th 2019 Financial Results of Operations
Golden, Colorado-June 19th, 2019-Vitro Diagnostics, Inc. (OTCQB: VODG), dba Vitro Biopharma, announced its 2nd quarter ended April 30th 2019 financial results of operations. Vitro Diagnostics Inc. (“Vitro Biopharma”) is pleased to announce a record 2nd quarter in Stem...
Vitro Biopharma 1st Quarter ended January 31st 2019 Financial Results of Operations
Golden, Colorado-March 21, 2018-Vitro Diagnostics, Inc. (OTCQB: VODG), dba Vitro Biopharma, announced its 1st quarter ended January 31st 2019 financial results of operations. Vitro Diagnostics Inc. (“Vitro Biopharma”) is pleased to announce a record 1st quarter in...
Vitro Biopharma 2018 CEO Shareholder Letter
Press Release Source: Vitro Diagnostics, Inc. Vitro Biopharma 2018 CEO Shareholder Letter:Record Revenues from Stem Cell Treatments Lead to 4th Quarter BreakevenCashflow & Growth...
Providing high quality commercialized cell lines, media, stem cell products & stem cell technology
Providing applications in stem cell research, drug discovery and STEM CELL therapies
Customer Service (303)-999-2130 Ext. 1
4621 Technology Drive Golden, CO 80403
Technical Support (303)-999-2130 Ext. 2
info@vitrobiopharma.com
Accounting (303)-999-2130 Ext. 3
Please click the image above to view our ISO 13485:2016.
Please click the image above to view our ISO 9001:2015 Certification.
Please click the image above to view our FDA registration.
